Gyre Therapeutics, Inc. (GYRE)
4.555
-1.86
(-28.94%)
USD |
NASDAQ |
Oct 30, 16:00
4.64
+0.08
(+1.87%)
After-Hours: 20:00
Gyre Therapeutics Gross Profit Margin (Quarterly) : 92.41% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 92.41% |
| March 31, 2026 | 94.55% |
| December 31, 2025 | 95.31% |
| September 30, 2025 | 94.67% |
| June 30, 2025 | 96.13% |
| March 31, 2025 | 95.95% |
| December 31, 2024 | 95.78% |
| September 30, 2024 | 96.24% |
| June 30, 2024 | 96.95% |
| March 31, 2024 | 96.40% |
| December 31, 2023 | 95.91% |
| September 30, 2023 | 96.30% |
| June 30, 2023 | 96.33% |
| March 31, 2023 | 95.49% |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | -14.74% |
| December 31, 2021 | -5.29% |
| September 30, 2021 | -4.05% |
| June 30, 2021 | -4.59% |
| March 31, 2021 | -3.95% |
| December 31, 2020 | -2.22% |
| September 30, 2020 | -6.72% |
| June 30, 2020 | -6.63% |
| Date | Value |
|---|---|
| March 31, 2020 | 72.48% |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | -6.64% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Cytokinetics, Inc. | 67.78% |
| Incyte Corp. | 91.91% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Anika Therapeutics, Inc. | 65.15% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -13.75% |
| Return on Assets | -11.65% |
| Return on Invested Capital | -13.60% |
| Profit Margin (Quarterly) | -49.03% |
| Operating Margin (Quarterly) | -47.62% |
| Return on Net Operating Assets | -27.26% |